Added text to state that the duration of primary chemotherapy ranges from 6 months to approximately 1 year. Also added text to state that a randomized clinical trial from the Children's Oncology Group showed that for patients presenting without metastases, the administration of cycles of cyclophosphamide, doxorubicin, and vincristine alternating with cycles of ifosfamide and etoposide at 2-week intervals achieved superior event-free survival (EFS) than alternating cycles at 3-week intervals (cited Womer et al. as reference 20).
Added text to state that the cumulative incidence of subsequent neoplasms in children treated for Ewing sarcoma between 1970 and 1986 at 25 years after diagnosis was 9.0%. Most of these patients received radiation therapy; comparable long-term data do not yet exist for significant numbers of patients who did not receive radiation therapy (cited Ginsberg et al. as reference 65).
Ewing Sarcoma: Localized Tumors
Revised text to state that patients randomly assigned to the every 2-week interval of treatment had an improved 5-year EFS (73% vs. 65%, P = .048) (cited Womer et al. as reference 14).
Ewing Sarcoma: Recurrent Tumors
Added Malempati et al. as reference 18.
This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.
In this article
WebMD Public Information from the National Cancer Institute
February 25, 2014
This information is not intended to replace the advice of a doctor.
Healthwise disclaims any liability for the decisions you make based on this